ROI-NJ, citybizlist, S&P Global, InvestorsHub, MarketScreener.com, and the Global Legal Chronicle report that Lowenstein client DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero Biopharmaceuticals Holdings, Inc., a privately held biopharmaceutical company focused on the development of its late stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. The Lowenstein deal team includes Michael J. Lerner, Steven M. Skolnick, Alan Wovsaniker, Kate Basmagian, Robert Bee, Justin Gindi, and Erica Perlmutter. View Lowenstein's news announcement about this transaction.